Rocket Lab Replaces $3B ATM with New $1.94B Program Tied to Iridium Deal
RKLB has more than doubled off its 52-week low of $37.57.
Summary
Rocket Lab replaced its $3B ATM with a new $1.94B program that adds forward sales and directs proceeds to the Iridium acquisition.
Key Events · Financing and Capital Events · RKLB
-
New ATM Program Replaces Prior $3B
Rocket Lab terminated its $3.0B ATM program effective August 6, 2026, and entered a new equity distribution agreement for the remaining $1,944,369,826.
-
Forward Sale Mechanisms Added
The new agreement permits initially priced and collared forward transactions, allowing Rocket Lab to sell borrowed shares through forward purchasers and receive proceeds at settlement.
-
Proceeds Earmarked for Iridium Acquisition
Net proceeds are intended to finance the cash portion of the $8 billion Iridium merger consideration, pay transaction fees, and repay Iridium debt if necessary.
-
Dilution Impact
At the assumed offering price of $80.04, selling the full $1.94B would issue approximately 24.3 million shares, increasing net tangible book value per share from $5.84 to $8.67.
Analysis · RKLB · Manufacturing
Rocket Lab terminated its prior $3.0 billion ATM program and replaced it with a new equity distribution agreement for the remaining $1.94 billion. The new program adds forward sale mechanisms and explicitly earmarks proceeds to fund the cash portion of the $8 billion Iridium acquisition. This is a material update because it changes the financing structure and links the offering directly to the pending merger, increasing potential dilution while providing a clear use of proceeds.
At the time of this filing, RKLB was trading at $80.45 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $48.6B. The 52-week trading range was $37.57 to $151.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.